JPH089897A - Coating composition for substances containing bitterness - Google Patents

Abstract

PURPOSE:To obtain a coated composition in which a bitter substance is coated with an acidic phospholipid as an effective ingredient, and capable of more effectively reducing the bitter taste of a food, a medicine, etc., than when bitter taste-reducing agents such as lecithin are used. CONSTITUTION:The objective composition for the bitter taste-having substance comprises a bitter substance such as a food or a medicine and a bitter taste- reducing agent containing an acidic phospholipid or its lyso compound (e.g. a monoacylglyceromonophosphate, monoacylglycerodiphosphate, diacylglyceromonophosphate, bisphosphatidic acid, bisphosphatidyl- monophosphatidic acid or bisphosphatidyl-lysophosphatidic acid preferably contained in a lipid mixture, and neutral lipids are contained in the lipid mixture in an amount of <=30wt.%) as an effective ingredient.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a coating composition for a bitterness-containing substance. In particular, the present invention is a food or its material,
Alternatively, the present invention relates to a coating composition of a bitterness-containing substance obtained by coating a substance having bitterness such as a drug with a bitterness reducing agent.

[0002]

2. Description of the Related Art Although there are many foods and pharmaceuticals containing bitter substances, most of the pharmaceuticals have bitter substances, and they are painful when ingested orally. Therefore, reduction of bitterness has become a major problem in formulation. As a method for reducing bitterness in currently used preparations, for example, a method of adding a sweetener and a flavoring agent (JP-A-2-56416: a method of using aspartame), microencapsulation, powder by a gastric-soluble coating agent A method of using a coating agent, a method of chemically modifying a drug, and a method of adding an inclusion compound (JP-A-3-236)
316) and various other methods. But,
Both methods have drawbacks such that it is difficult to completely suppress the bitterness and that they can be used only for limited drugs. In addition to the above method,
A method of adding an oil and fat component to a drug having a bitter taste, particularly a method of adding lecithin (phosphatidylcholine) or kephaline alone or in a mixture (Japanese Patent Publication No. 55-8966) and a method of adding lecithin (phosphatidylcholine) (JP-A-SHO). 62-265234) has also been proposed. However, according to the study by the present inventor, even the above method has not yet sufficiently reduced the bitterness. In particular, it is often difficult for infants and the elderly to take a drug as a solid preparation, and in such a case, a liquid form such as a syrup is used. However, there is currently no effective method for removing the bitterness of liquid drugs such as syrups.

[0003] Foods often contain various bitter substances such as the bitterness of amino acids and peptides obtained from protein degradation products, the bitterness present in fruit juice, and the bitterness derived from added flavors. The presence of substances generally reduces the quality of food products. Examples of methods for removing bitterness in foods include a method using an adsorbent (JP-A-55-108254), a method using an inclusion compound (JP-A-61-40260), and a sweetener. A method of adding (Japanese Patent Application Laid-Open No. 60-9774) is known. However, these methods have many problems such that the bitterness cannot be sufficiently suppressed and the taste quality of food is changed.

[0004]

SUMMARY OF THE INVENTION An object of the present invention is to provide a food having bitterness, or a novel coating composition of a bitterness-containing substance in which the bitterness of a drug is reduced.

[0005]

Generally, a substance having a bitter taste has a hydrophobic group, and by the action of the hydrophobic group, the lipid-lipid and the lipid-protein present on the taste-receptive membrane of taste cells of the tongue are People who ingest that substance tend to
A bitter taste is felt through this adsorption effect. It has also been confirmed in studies using liposomes composed of phospholipids that substances having stronger bitterness have stronger affinity with lipids. That is, when a substance having a bitter taste is added to a liposome into which a fluorescent dye is incorporated, the substance having a bitter taste is adsorbed on the liposome membrane, which causes the release of the fluorescent dye. It has been confirmed that the emission of the fluorescent dye is greater in the substance having a stronger bitterness. That is,
It shows that the bitter substance is easily adsorbed on the phospholipid membrane. It has also been confirmed that, depending on the type of phospholipid, direct adsorption to the bitterness-receptive membrane of taste cells causes bitterness-reception inhibition.

[0006] The present inventor has conducted diligent research by utilizing the characteristics of the above-mentioned substances having a bitter taste and paying attention to the bitterness-accepting mechanism carried out in the taste tract and the interaction between the bitter substances and lipids. . As a result, they have found that acidic phospholipids and lysoacidic phospholipid lipids are very effective in reducing bitterness. It has not been known at all that such acidic phospholipid or its lyso form independently has a strong bitterness reducing action.

The present invention resides in a coating composition for a bitterness-containing substance, which comprises a substance having a bitterness and a bitterness-reducing agent containing the acidic phospholipid or its lyso form coating the same as an active ingredient.

The present invention preferably has the following aspects. (1) The acidic phospholipid and its lyso form are selected from the group consisting of phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, cardiolipin, and these lyso forms. (2) The acidic phospholipid or its lyso form is present in the lipid mixture, and the amount of neutral lipid present in the lipid mixture is 2
It is 5% by weight or less (particularly 20% by weight or less).

(3) The acidic phospholipid or its lyso form is present in the lipid mixture, and the content of the acidic phospholipid or its lyso form in the lipid mixture is 60% by weight or more (particularly 70%).
% Or more). (4) The acidic phospholipid or its lyso form is phosphatidic acid or lysophosphatidic acid, and phosphatidic acid and / or lysophosphatidic acid is contained in the lipid mixture in an amount of 5% by weight or more (more preferably 20% by weight or more, particularly preferably 50% by weight). % Or more) present. (5) The acidic phospholipid or its lyso form is present in the lipid mixture, and the amount of neutral phospholipid present in the lipid mixture is not more than twice the amount of the phospholipid present (more preferably 1
/ 2 or less, particularly 1/5 or less, and most preferably 1/50 or less).

(6) The coating composition is a food, and the coating amount of the bitterness reducing agent is 0.1 to 20% by weight (more preferably 0.5 to 15% by weight) based on the total amount of the food as an active ingredient. %, Particularly preferably 1 to 10% by weight, most preferably 1 to 5% by weight).

(7) The coating composition is a drug, and the coating amount of the bitterness-reducing agent is 0.05 to 50% by weight (more preferably 0.1 to 50% by weight) based on the total amount of the drug as its active ingredient.
30% by weight, particularly preferably 0.5 to 20% by weight, most preferably 1 to 10% by weight).

The coating composition of the bitterness-containing substance of the present invention will be described below. First, the bitterness-reducing agent used in the coating composition of the bitterness-containing substance of the present invention (hereinafter sometimes simply referred to as the coating composition of the present invention) will be described.
The bitterness reducing agent used in the present invention contains an acidic phospholipid or a lyso form thereof as an active ingredient. The acidic phospholipid is one in which the total charge is negatively charged under the condition of physiological saline (pH 7.0). As acidic phospholipids,
Examples include phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, and cardiolipin. Examples of the lyso form (lysoacid phospholipid) include lysophosphatidylserine, lysophosphatidic acid, lysophosphatidylinositol, and lysophosphatidylglycerol.

The acidic phospholipid or its lyso form used as the bitterness-reducing agent of the present invention can be obtained by extracting and separating from various animal organs and various plant tissues including soybean, egg yolk and wheat germ. . Examples of the extraction method that can be used include extraction with an organic solvent that utilizes the difference in polarity. As a separation method, a method of adsorbing on a silica gel column and then eluting with an organic solvent can be mentioned. In order to obtain the acidic phospholipid or its lyso form, a method of modifying the phospholipid analog separated by extraction, separation and purification by chemical modification and / or enzymatic treatment can also be used. As a specific method thereof, phospholipase D derived from plants such as oil seeds (JP-A-2-312552), cabbage and rice bran, or phospholipase D produced by a microorganism (JP-A-2-312551) is used. , A method of hydrolyzing phosphatidylcholine, which is a neutral phospholipid, to obtain phosphatidic acid, or transesterification of a phosphate group using phospholipase D to convert phosphatidylcholine into phosphatidylglycerol (JP-A-3-22991) or phosphatidylserine. And the like.

Further, in the bitterness reducing agent of the present invention, chemically synthesized acidic phospholipid or its lyso form can be used. Specific synthesis methods include phosphoric acid esterification of diglyceride, monoglyceride phosphoric acid ester, glycerophosphoric acid fatty acid esterification, monoglyceride phosphoric acid esterification, and glycerophosphoric acid fatty acid esterification. Examples of acidic phospholipids and their lyso forms obtained by the chemical synthesis method as described above, monoacyl glycero monophosphate, monoacyl glycero diphosphate, diacyl glycero monophosphate, bisphosphatidic acid, bisphosphatidyl monophosphatidic acid, Examples thereof include bisphosphatidyllysophosphatidic acid. Further, hydrogenated acidic phospholipids and hydrogenated lyso acidic phospholipids can also be used.

The acidic phospholipid or its lyso form, which is the active ingredient of the bitterness-reducing agent of the present invention, is obtained from a natural product or by chemical synthesis as described above. Therefore, the acidic phospholipid or its lyso form is obtained as a lipid mixture and is often used as a lipid mixture. In that case, in order to obtain a higher bitterness-reducing effect, it is preferable that the content of the acidic phospholipid or its lyso form is large, and specifically, the lipid mixture should contain 20% by weight or more. Is preferable, and it is more preferable that the content is 40% by weight or more. Particularly, it is preferable that the content is 60% by weight or more, and 70% by weight or more.

Among the acidic phospholipids and their lyso forms, phosphatidic acid and lysophosphatidic acid have been confirmed to have a strong bitterness-reducing action.
Therefore, in the bitterness reducing agent of the present invention, it is preferable to use phosphatidic acid or lysophosphatidic acid, and it is particularly preferable to use phosphatidic acid. The phosphatidic acid or lysophosphatidic acid is preferably present in the lipid mixture in an amount of 5% by weight or more, more preferably 20% by weight or more, and particularly preferably 50% by weight or more.

In addition to the acidic phospholipid or its lyso form, the lipid mixture usually contains other lipid components. Examples of the lipid component other than the acidic phospholipid and its lyso form include neutral phospholipids (eg, phosphatidylcholine, phosphatidylethanolamine, and lyso forms thereof), neutral lipids (eg, triglyceride, diglyceride, monoglyceride), fatty acids , Sterol lipids, glycolipids and the like.

The study conducted by the present inventor has revealed that the bitterness-reducing effect can be further enhanced by reducing the amount of neutral lipids or neutral phospholipids present in the lipid mixture. Therefore, when a lipid mixture is used as the bitterness-reducing agent of the present invention, the amount of neutral lipid present in the lipid mixture is preferably 30% by weight or less, more preferably 25% by weight or less, and particularly 20% by weight or less. It is less than or equal to weight%. The amount of neutral phospholipid present in the lipid mixture is preferably 50% by weight or less, more preferably 30% by weight or less, and particularly 10% by weight or less. The ratio of the neutral phospholipid to the acidic phospholipid or its lyso form in the lipid mixture is preferably 2 times or less (neutral phospholipid / acid phospholipid and its lyso form), more preferably 1 / 2 or less, particularly 1/5 or less, most preferably 1/50 or less. In order to increase the amount of acidic phospholipid and its lyso form in the lipid mixture and reduce the amount of neutral lipid, the lipid mixture containing these components may be enzymatically decomposed,
A method of performing a treatment such as acetone treatment and membrane separation after the solvent fractionation treatment can be used.

The bitterness-reducing agent used for coating in the present invention may be powdered, granular, troche-like solid, paste-like or syrup-like in accordance with known preparation methods depending on the conditions of use. It can be liquid. An antioxidant is preferably added to the bitterness reducing agent used for coating in the present invention in order to prevent and stabilize oxidation. Examples of preferable antioxidants include tocopherol and polyphenols.

The coating composition for a bitterness-containing substance according to the present invention is preferably a food or a drug. That is, in the present invention, the substance having a bitterness is preferably a food having a bitterness (including a food material and a beverage) or a drug having a bitterness.

The food having a bitterness to be coated according to the present invention is not particularly limited as long as it has a solid state (including powder, granules, etc.) so that the surface thereof can be coated with a bitterness reducing agent. Such foods include, for example, soybean foods such as pickles and yuba, processed fish products such as fish meat, surimi and roe, fermented products such as nuts and natto, processed meat products and dairy products such as cheese. , Chocolates and other confectioneries, flavored candies, cigarettes, solid health foods and the like. In addition to the above, it is also possible to coat a liquid such as fruit juice or vegetable juice processed into a solid such as powder.

In the coating composition of the present invention, the bitterness reducing agent is preferably coated on the entire surface of the food,
The entire surface does not necessarily have to be covered. Especially in food, the shape is not all uniform,
If at least a part of the surface is covered with the bitterness reducing agent, the effect of the present invention can be obtained. The coating state of the bitterness-reducing agent on foods, pharmaceuticals, etc., for example, adheres to the surface,
It may be adsorbed. For coating a food having a bitter taste, a method of spraying a dispersion containing a bitterness-reducing agent on the food with a spray or the like, for example, a pan coating method is usually used. Further, depending on the target food or drug, a method of immersing the food in the dispersion liquid can be used. After the coating, a drying process may be performed depending on the case.

In the present invention, when the coating composition is a food, the coating amount of the bitterness reducing agent as an active ingredient (acidic phospholipid or its lyso form) is 0.05 based on the total amount of the food. Is preferably 30 to 30% by weight, more preferably 0.1 to 20% by weight, still more preferably 0.5 to 15% by weight, particularly preferably 1 to 10% by weight,
Most preferably, it is 1 to 5% by weight. When coating,
It is also possible to use a binder such as a water-soluble polymer (eg, carboxymethyl cellulose, gelatin, etc.) or other additives that can be used in combination with foods.

The drug having a bitterness to be coated in the present invention is not particularly limited, and a drug having a bitterness which has been conventionally used as a medicine can be a coating target. Particularly, it is effective for coating an acid addition salt of a basic drug (for example, strychinene, quinine, papaverine, berberine, promethazine, brucine, propranolol, chlorpromazine, etc.). Specific examples of the basic drug acid addition salt can be used for the basic drug hydrochloride, nitrate, sulfate, acetate, citrate, carbonate and other mineral acid salts, and / or organic acid salts. .

Examples of the dosage form of the coating composition of the present invention include solid preparations such as capsules, granules, fine granules, pills, tablets, troches, and dry syrups. In the present invention, granules, pills, powders or tablets are preferable.

A known method can be used for producing the solid preparation to be coated. Therefore, upon formulation, one or more kinds of conventionally used additives can be used in combination. Examples of the additive include an excipient, a binder, a disintegrant, a lubricant, a fluidizing agent, a coating agent, a corrigent, a masking agent, a fragrance, and an antioxidant. Further, as the granulator used in the formulation step, a planetary mixer, a stirring granulator, a high speed mixing granulator, an extrusion granulator, a fluidized bed granulator, a centrifugal tumbling fluidized granulator, a roller compactor, etc. Can be mentioned.

As a method for coating the drug (solid preparation) with the bitterness-reducing agent, a method conventionally used for coating a preparation is used. For example, a fluidized bed coating method, a pan coating method and the like can be mentioned. It is also possible to coat the surface of fine granules of a drug having a bitterness with a bitterness-reducing agent, and then use the resulting granules to prepare granules and the like according to a usual formulation method. Upon coating, a binder such as a water-soluble polymer (eg, carboxymethyl cellulose, gelatin, etc.) that can be used in pharmaceuticals, or other additives can be used in combination.

In the present invention, when the coating composition is a drug, the coating amount of the bitterness reducing agent is 0.01 to 60 with respect to the total amount of the drug as its active ingredient (acidic phospholipid or its lyso form). %, More preferably 0.05 to 50% by weight, further preferably 0.1 to 30% by weight, particularly preferably 0.5 to 20% by weight, most preferably 1 to 10% by weight. .

In the medicine, 0.01 to 1000 parts of the acidic phospholipid, which is the active ingredient of the bitterness-reducing agent, or its lyso form is used per 1 part of the main ingredient which is a medicinal ingredient showing bitterness ( More preferably, 0.1 part to 100 parts)
It is preferably added so that the content is (weight ratio). When there are two or more types of medicinal components having bitterness, the total weight is 1 part.

[0030]

EXAMPLES The present invention will be described more specifically below with reference to Examples and Comparative Examples. In the following, "part"
Indicates "part by weight" and "%" indicates "% by weight".

(Preparation of sample for bitterness-reducing agent containing acidic phospholipid of the present invention and its lyso form) 500 m equipped with a stirrer
A commercially available defatted lecithin (trade name:
SLPW-SP, Trulecithin Industry Co., Ltd.) 20 g
Take 0.1M Tris-HCl buffer (pH 6-8) 1
25 mL was added, and hexane / ethyl acetate (2
(1/1, V / V) 340 mL was added and stirred. Calcium chloride aqueous solution (1M concentration) 150m was added to the obtained mixture.
L, then phospholipase D of microbial origin (Stre
After adding 150 mL of an aqueous solution containing 15 units of ptomyces Chromofuscus derived from Asahi Kasei Kogyo Co., Ltd., stirring was continued for 14 hours while maintaining the temperature of the mixture at 30 ° C.
After the reaction, the reaction product was allowed to stand and the solvent layer was separated. The solvent layer was evaporated under reduced pressure. Analysis of the lipid mixture components obtained as a residue was performed using a thin layer silica gel plate (Kies
elgel: manufactured by Merck & Co., Inc.). Sulfuric acid coloring was used for detection. The results are shown in Table 1.

[0032]

[Table 1] Table 1 ──────────────────────────────────── Content of components in lipid mixture ( %) ──────────────────────────────────── (neutral phospholipid) phosphatidylcholine 0 phosphatidylethanolamine 0 ──────────────────────────────────── (Acidic phospholipids) Phosphatidylinositol 7.8 Phosphatidic acid 54. 2 Phosphatidylserine 0.1 Lysophosphatidic acid 0.5 ──────────────────────────────────── Neutral Lipid 18.4 Glycolipid 19.0 ─────────────────────────────────────

Example 1 A coated granule having the following composition (I and II: 100 parts in total) was produced by a tumbling granulation method. Composition I Quinine hydrochloride (main ingredient) 1 part Corn starch 35 parts Lactose 54.5 parts HPC 3.5 parts (hydroxypropyl cellulose) Composition II Sample (bitterness reducing agent) 1 part HPC 5 parts (hydroxypropyl cellulose)

(Preparation / Coating Method) With the above composition I, core particles were granulated using a high speed mixer. The obtained granulated product is dried and classified, and then the particle surface is treated with the above-mentioned compound II.
Was coated with a fluidized bed spray. In this way, a granule in which the surface of the particles of composition I was coated with the bitterness reducing agent was obtained. As a control, the above composition I
Granules having a composition (compounding HPC at 6 parts) without adding the bitterness reducing agent sample in I, and the above composition I as a comparative example.
Granules having a composition in which lecithin (phosphatidylcholine) was used instead of the bitterness reducing agent sample in I were prepared in the same manner. Regarding the intensity of bitterness, 10 to 15 healthy men and women with normal taste were selected as subjects, 0.5 g of each of the obtained granules was contained in the mouth, and the intensity of bitterness after 30 seconds was sensory evaluated. It evaluated by the method. The evaluation used the following equivalent concentration test method. The results are shown in Table 2.

(Equivalent Concentration Test Method) What is the equivalent concentration test method?
A standard solution was prepared in advance so that the intensity of bitterness was equidistant, and this standard solution and the liquid agent prepared above were compared by sensory evaluation of the subjects, and the corresponding bitterness intensity was expressed by the average value. Is the way. Here, as the standard liquid, a liquid having a bitterness intensity adjusted to 10 levels with quinine sulfate, which is a typical bitter substance, was used. Since the sensory intensity such as taste is proportional to the logarithm of the concentration, the concentration interval is not constant, but the intensity of bitterness to be sensed is equal. The standard solution is shown below. ──────────────────────────────────── Quinine sulfate quinine sulfate Bitter strength Concentration (g / 100mL) Bitter strength Concentration (g / 100mL) ──────────────────────────────────── 1 0.00022 6 0.0037 2 0.00048 7 0.0058 3 0.0009 8 0.0094 4 0.0015 9 0.015 5 0.0023 10 0.0245 ────────────────── ──────────────────

[0036]

[Table 2] Table 2 ──────────────────────────────────── Granules Bitterness intensity (average value) ──────────────────────────────────── Control 8.3 Coated with the bitterness reducing agent sample of the present invention Granules coated with 2.9 Lecithin-coated granules 7.5 ──────────────────────────────────── The results in Table 2 show that the bitterness can be significantly reduced by coating the surface of the granule with the bitterness reducing agent of the present invention.

[Example 2] The same as Example 1 except that the composition I and the composition II (coating agent) of the granules were changed as follows (the composition was 100 parts in total). Coated granules were prepared. Composition I Quinine hydrochloride (main ingredient) 10 parts Corn starch 27 parts Lactose 44.5 parts HPC 3.5 parts (hydroxypropyl cellulose) Composition II sample (bitterness reducing agent) 10 parts HPC 5 parts (hydroxypropyl cellulose) Also as a control , Coated granules having a composition (composition of HPC of 15 parts) in which the bitterness-reducing agent sample in the composition II is not added, and as a comparative example, lecithin (phosphatidylcholine) is used instead of the bitterness-reducing agent sample in the composition II. Each of the coated granules having the composition (1) was prepared in the same manner.
The intensity of bitterness of each of the obtained coated granules was evaluated using the same method as in Example 1. Table 3 shows the results.

[0038]

[Table 3] Table 3 ──────────────────────────────────── Granules Bitterness intensity (average value) ──────────────────────────────────── Control 9.7 Coated with the bitterness reducing agent of the present invention Granules 4.6 Granules coated with lecithin 9.2 ─────────────────────────────────────

From the results shown in Table 3, it is understood that the bitterness can be remarkably reduced by coating the surface of the granule with the bitterness reducing agent of the present invention.

Example 3 A granule coated with the bitterness-reducing agent sample of the present invention was prepared in the same manner as in Example 2 except that the quinine hydrochloride as the main ingredient was replaced with the drug having the following bitterness, and The bitterness intensity was evaluated. As a result, it was confirmed that the bitterness was similarly reduced for all the granules. Drugs used: Promethazine, Chlorpromazine, Papaverine, Propranolol, Berberine

[Example 4] Oren-gedokuto extract powder was selected as a drug having a bitter taste, and Kampo extract granules containing 20% of this powder were prepared by a dry granulation method. Separately, an aqueous solution containing 5 parts of the bitterness reducing agent sample and 5 parts of HPC is prepared,
This was coated on the surface of the above granules. It was confirmed that the resulting granules had almost no bitter taste.

Example 5 A tablet having the composition (unit: part) shown in Table 4 below was produced by the following production method. (Preparation Method of Tablets) Formulation (250 mg / tablet) was prepared by direct powder compression method with the composition I. Thereafter, the surface of the obtained tablets was coated with the coating liquid of composition II by the pan coating method. In this way, tablets C and D according to the present invention coated with the bitterness-reducing agent sample of the present invention and the corresponding granules C-1 and D-1 for comparison, respectively, were obtained. Each of the tablets thus obtained was dissolved in the mouth while rolling on the tongue for 30 seconds, and the bitterness at that time was evaluated in the same manner as in Example 1. The results are shown in Table 4.

[0043]

[Table 4] Table 4 ──────────────────────────────────── Inventive product Comparative product Inventive product Comparative product C C-1 D D-1 ──────────────────────────────────── (Tablet composition I) Quinine hydrochloride (main ingredient) 1 1 10 10 Corn starch 30 30 30 30 30 Lactose 55 60 46 51 Talc 1 1 1 1 HPC 3 3 3 3 3 ─────────────────── ────────────────── (Coating liquid composition II) Sample (bitterness reducing agent) 5 0 5 0 HPMC 5 5 5 5 5 ────────── ─────────────────────────── Evaluation results (bitterness intensity) 2.5 8.0 3.5 9.0 9.0 ──── ─────────── ──────────────────── HPMC: Hydroxymethylcellulose The coating liquid is prepared by dispersing 10% of each sample (bitterness reducing agent) in 10% HPMC aqueous solution. It was used.

From the results shown in Table 4, it is understood that the bitterness can be significantly reduced by coating the surface of the tablet with the bitterness-reducing agent of the present invention.

Example 6 A tablet coated with the bitterness-reducing agent sample of the present invention was prepared in the same manner as above, except that the quinine hydrochloride, which is the main drug in Example 5, was replaced with the drug having the following bitterness. Similarly, the intensity of bitterness was evaluated. as a result,
It was confirmed that the bitterness was reduced for all the coated tablets. Drugs used: Promethazine, Chlorpromazine, Papaverine, Propranolol, Berberine

[Example 7] Using quinine hydrochloride powder as a substance having a bitter taste, a coating solution comprising 1 part of quinine hydrochloride and 1 part of the above-mentioned sample (bitterness reducing agent) and 1 part of HPC (hydroxypropyl cellulose) was used. It was coated with a fluidized bed spray and granulated. Using quinine hydrochloride fine particles surface-coated with the obtained bitterness reducing agent sample of the present invention,
Powders, granules, and tablets were prepared with the following compositions (parts). Powders were prepared using a V-mixer, granules were prepared using the fluid bed granulation method, and tablets were prepared using the direct powder compression method.

──────────────────────────────────── Composition Powders Granules Tablets ─────── ────────────────────────────── Quinine hydrochloride with surface treatment 3 3 3 Corn starch 30 30 30 Lactose 67 64 64 63 Talc − − −− 1 HPC −− 33 3 ─────────────────────────────────────

It was confirmed that the resulting powders, granules and tablets all had almost no bitter taste.

[Example 8] "Salmon roe" desalted was immersed in a 5% aqueous dispersion of a bitterness-reducing agent sample of the present invention for 30 minutes to adsorb the sample on the surface of "Salmon roe". When the obtained "Kazunoko" was eaten, its peculiar bitterness was moderately reduced and it was delicious.

[Example 9] After removing "warabi" known as a wild vegetable having a strong bitterness by a conventional method, it was immersed in a 10% aqueous dispersion of the bitterness-reducing agent sample of the present invention for 30 minutes to prepare "warabi". The sample was adsorbed on the surface. Obtained "Bracken"
When it was eaten, the peculiar bitterness was moderately suppressed, and the original flavor of “BARABI” was highlighted, and it was delicious.

[0051]

The coating composition of the bitterness-containing substance of the present invention comprises:
Since it is coated with acidic phospholipid or its lyso form, which has an excellent bitterness-suppressing action, the bitterness can be reduced more effectively than when a conventional bitterness-suppressing agent such as lecithin is used. Therefore, the bitterness can be suppressed even with a drug that is a strong bitter substance, and a drug that is very easy to take can be provided. In addition, since the bitterness is removed from the food, other umami is emphasized, and therefore the food can be used as a more delicious food.

Claims (7)

[Claims] 1. A coating composition for a bitterness-containing substance, which comprises a substance having a bitterness and a bitterness-reducing agent containing the acidic phospholipid or its lyso form coating the same as an active ingredient. 2. The coating of a bitterness-containing substance according to claim 1, wherein the acidic phospholipid or its lyso form is present in the lipid mixture, and the amount of neutral lipid present in the lipid mixture is 30% by weight or less. Composition. 3. The bitterness-containing substance according to claim 1, wherein the phospholipid or the lyso form thereof is present in the lipid mixture, and the content of the phospholipid or the lyso form thereof in the lipid mixture is 20% by weight or more. Coating composition. 4. The coating composition for a bitterness-containing substance according to claim 1, wherein the bitterness-reducing agent contains both an acidic phospholipid and a lyso form thereof. 5. The phospholipid or its lyso form is present in the lipid mixture, and the amount of the neutral phospholipid present in the lipid mixture is not more than twice the content of the phospholipid or its lyso form. A coating composition of the bitterness-containing substance according to 1. 6. The coating composition for a bitterness-containing substance according to claim 1, wherein the phospholipid and its lyso form are phosphatidic acid and lysophosphatidic acid. 7. The coating composition for a bitterness-containing substance according to claim 1, wherein the bitterness-containing substance is a food or a drug.